vs
爵士制药（JAZZ）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是Rackspace Technology, Inc.的1.8倍（$1.2B vs $682.8M），爵士制药净利率更高（17.0% vs -4.8%，领先21.8%），爵士制药同比增速更快（10.1% vs -0.4%），爵士制药自由现金流更多（$345.8M vs $56.0M），过去两年爵士制药的营收复合增速更高（15.2% vs -0.6%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
JAZZ vs RXT — 直观对比
营收规模更大
JAZZ
是对方的1.8倍
$682.8M
营收增速更快
JAZZ
高出10.5%
-0.4%
净利率更高
JAZZ
高出21.8%
-4.8%
自由现金流更多
JAZZ
多$289.8M
$56.0M
两年增速更快
JAZZ
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $682.8M |
| 净利润 | $203.5M | $-32.7M |
| 毛利率 | — | 17.6% |
| 营业利润率 | 21.2% | -0.5% |
| 净利率 | 17.0% | -4.8% |
| 营收同比 | 10.1% | -0.4% |
| 净利润同比 | 6.5% | 41.6% |
| 每股收益（稀释后） | $3.34 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRXT
| Q4 25 | $1.2B | $682.8M | ||
| Q3 25 | $1.1B | $671.2M | ||
| Q2 25 | $1.0B | $666.3M | ||
| Q1 25 | $897.8M | $665.4M | ||
| Q4 24 | $1.1B | $685.6M | ||
| Q3 24 | $1.1B | $675.8M | ||
| Q2 24 | $1.0B | $684.9M | ||
| Q1 24 | $902.0M | $690.8M |
净利润JAZZRXT
| Q4 25 | $203.5M | $-32.7M | ||
| Q3 25 | $251.4M | $-67.1M | ||
| Q2 25 | $-718.5M | $-54.5M | ||
| Q1 25 | $-92.5M | $-71.5M | ||
| Q4 24 | $191.1M | $-56.0M | ||
| Q3 24 | $215.1M | $-186.6M | ||
| Q2 24 | $168.6M | $25.0M | ||
| Q1 24 | $-14.6M | $-640.6M |
毛利率JAZZRXT
| Q4 25 | — | 17.6% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | — | 20.3% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | 19.2% |
营业利润率JAZZRXT
| Q4 25 | 21.2% | -0.5% | ||
| Q3 25 | 5.1% | -5.1% | ||
| Q2 25 | -65.6% | -3.8% | ||
| Q1 25 | -6.2% | -5.8% | ||
| Q4 24 | 17.5% | -4.2% | ||
| Q3 24 | 24.7% | -25.7% | ||
| Q2 24 | 19.5% | -7.9% | ||
| Q1 24 | 7.3% | -94.5% |
净利率JAZZRXT
| Q4 25 | 17.0% | -4.8% | ||
| Q3 25 | 22.3% | -10.0% | ||
| Q2 25 | -68.7% | -8.2% | ||
| Q1 25 | -10.3% | -10.7% | ||
| Q4 24 | 17.6% | -8.2% | ||
| Q3 24 | 20.4% | -27.6% | ||
| Q2 24 | 16.5% | 3.7% | ||
| Q1 24 | -1.6% | -92.7% |
每股收益（稀释后）JAZZRXT
| Q4 25 | $3.34 | $-0.13 | ||
| Q3 25 | $4.08 | $-0.28 | ||
| Q2 25 | $-11.74 | $-0.23 | ||
| Q1 25 | $-1.52 | $-0.31 | ||
| Q4 24 | $2.97 | $-0.20 | ||
| Q3 24 | $3.42 | $-0.82 | ||
| Q2 24 | $2.49 | $0.11 | ||
| Q1 24 | $-0.23 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $105.8M |
| 总债务越低越好 | $5.4B | $2.7B |
| 股东权益账面价值 | $4.3B | $-1.2B |
| 总资产 | $11.7B | $2.8B |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
现金及短期投资JAZZRXT
| Q4 25 | $1.4B | $105.8M | ||
| Q3 25 | $1.3B | $99.5M | ||
| Q2 25 | $1.2B | $103.9M | ||
| Q1 25 | $1.9B | $128.0M | ||
| Q4 24 | $2.4B | $144.0M | ||
| Q3 24 | $2.2B | $157.1M | ||
| Q2 24 | $1.4B | $190.2M | ||
| Q1 24 | $1.4B | $282.6M |
总债务JAZZRXT
| Q4 25 | $5.4B | $2.7B | ||
| Q3 25 | $5.4B | $2.8B | ||
| Q2 25 | $5.4B | $2.8B | ||
| Q1 25 | $5.4B | $2.8B | ||
| Q4 24 | $6.1B | $2.8B | ||
| Q3 24 | $6.1B | $2.8B | ||
| Q2 24 | $5.7B | $2.9B | ||
| Q1 24 | $5.7B | $3.0B |
股东权益JAZZRXT
| Q4 25 | $4.3B | $-1.2B | ||
| Q3 25 | $4.0B | $-1.2B | ||
| Q2 25 | $3.7B | $-1.1B | ||
| Q1 25 | $4.2B | $-1.1B | ||
| Q4 24 | $4.1B | $-1.0B | ||
| Q3 24 | $4.2B | $-949.7M | ||
| Q2 24 | $3.8B | $-756.2M | ||
| Q1 24 | $3.7B | $-787.2M |
总资产JAZZRXT
| Q4 25 | $11.7B | $2.8B | ||
| Q3 25 | $11.4B | $2.8B | ||
| Q2 25 | $10.9B | $2.9B | ||
| Q1 25 | $11.5B | $3.0B | ||
| Q4 24 | $12.0B | $3.1B | ||
| Q3 24 | $12.3B | $3.1B | ||
| Q2 24 | $11.4B | $3.4B | ||
| Q1 24 | $11.3B | $3.5B |
负债/权益比JAZZRXT
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $56.0M |
| 自由现金流率自由现金流/营收 | 28.9% | 8.2% |
| 资本支出强度资本支出/营收 | 1.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $90.6M |
8季度趋势，按日历期对齐
经营现金流JAZZRXT
| Q4 25 | $362.5M | $59.7M | ||
| Q3 25 | $474.6M | $70.7M | ||
| Q2 25 | $88.9M | $8.4M | ||
| Q1 25 | $429.8M | $12.6M | ||
| Q4 24 | $398.6M | $54.3M | ||
| Q3 24 | $398.7M | $51.8M | ||
| Q2 24 | $331.4M | $24.1M | ||
| Q1 24 | $267.2M | $-90.3M |
自由现金流JAZZRXT
| Q4 25 | $345.8M | $56.0M | ||
| Q3 25 | $459.4M | $42.7M | ||
| Q2 25 | $75.9M | $-12.4M | ||
| Q1 25 | $415.9M | $4.3M | ||
| Q4 24 | $385.3M | $34.4M | ||
| Q3 24 | $388.0M | $27.3M | ||
| Q2 24 | $324.3M | $-14.5M | ||
| Q1 24 | $260.3M | $-118.4M |
自由现金流率JAZZRXT
| Q4 25 | 28.9% | 8.2% | ||
| Q3 25 | 40.8% | 6.4% | ||
| Q2 25 | 7.3% | -1.9% | ||
| Q1 25 | 46.3% | 0.6% | ||
| Q4 24 | 35.4% | 5.0% | ||
| Q3 24 | 36.8% | 4.0% | ||
| Q2 24 | 31.7% | -2.1% | ||
| Q1 24 | 28.9% | -17.1% |
资本支出强度JAZZRXT
| Q4 25 | 1.4% | 0.5% | ||
| Q3 25 | 1.3% | 4.2% | ||
| Q2 25 | 1.2% | 3.1% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 1.2% | 2.9% | ||
| Q3 24 | 1.0% | 3.6% | ||
| Q2 24 | 0.7% | 5.6% | ||
| Q1 24 | 0.8% | 4.1% |
现金转化率JAZZRXT
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | 0.96× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
